Inpharma Weekly

, Volume 985, Issue 1, pp 11–12 | Cite as

Peptide-based EBV vaccine in phase I trial

  • Jo Barnes
Newsletter Article


The first clinical study of a synthetic peptide-based vaccine against the Epstein-Barr virus (EBV) is now underway. Researchers are hopeful that the vaccine, which contains a cytotoxic T-lymphocyte (CTL) epitope, may protect against EBV immunopathology. Inpharma spoke to Dr Andreas Suhrbier, from the Queensland Institute of Medical Research, Brisbane, Australia, about the current phase I trial and the potential applications for an EBV vaccine in protecting against infectious mononucleosis (glandular fever) and the development of post-transplant lymphoproliferative disease (PTLD).


Tetanus Toxoid Latent Membrane Protein Infectious Mononucleosis MCMV Infection Peptide Component 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Jo Barnes

There are no affiliations available

Personalised recommendations